Adjuvants in allergen-specific immunotherapy: New research results fresh from the Blank lab!

In experimental HDM AIT, a 220-fold reduced allergen dose is equally effective in control of allergic inflammation when HDM allergoids instead of extracts are applied.

Low-dose non-adjuvanted allergoid AIT is less effective in inducing a potentially protective IgG1 response.

Combining low-dose allergoid AIT with the adjuvant MCT or the adjuvant system MCT+MPL promotes Th1-inducing mechanisms and robust B-cell activation.

https://www.youtube.com/watch?v=MpeuN_Khw_8

https://onlinelibrary.wiley.com/doi/full/10.1111/all.15012